Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas

Journal of Hepatology

Volumn 41, Issue 1, 2004, Pages 112-118

  Bläker, Michael ^a   Schmitz, Michael ^a   Gocht, Andreas ^a   Burghardt, Sylvia ^a   Schulz, Martina ^a   Bröring, Dieter C ^a   Pace, Andrea ^a   Greten, Heiner ^a   De Weerth, Andreas ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Hepatocellular carcinoma; Somatostatin; Somatostatin receptors

Indexed keywords

OLIGONUCLEOTIDE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHILD; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LIVER; LIVER NEOPLASMS; MEMBRANE PROTEINS; MIDDLE AGED; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 3442880408     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.03.018     Document Type: Article

References (34)

1. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J., et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 179:1973;77-79
2. Patel Y.C. Somatostatin and its receptor family. Front Neuroendocrinol. 20:1999;157-198
3. Lamberts S.W., van der Lely A.J., de Herder W.W., Hofland L.J. Octreotide. N Engl J Med. 334:1996;246-254
4. Treiber G. Systemic treatment of hepatocellular carcinoma. Dig Dis. 19:2001;311-323
5. Kouroumalis E., Skordilis P., Thermos K., Vasilaki A., Moschandrea J., Manousos O.N. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 42:1998;442-447
6. Samonakis D.N., Moschandreas J., Arnaoutis T., Skordilis P., Leontidis C., Vafiades I., et al. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep. 9:2002;903-907
7. Dimitroulopoulos D., Xinopoulos D., Tsamakidis K., Zisimopoulos A., Andriotis E., Markidou S., et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology. 49:2002;1245-1250
8. Raderer M., Hejna M.H., Muller C., Kornek G.V., Kurtaran A., Virgolini I., et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol. 16:2000;1197-1201
9. Yuen M.F., Poon R.T., Lai C.L., Fan S.T., Lo C.M., Wong K.W., et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 36:2002;687-691
10. Reubi J.C., Zimmermann A., Jonas S., Waser B., Neuhaus P., Laderach U., et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut. 45:1999;766-774
11. Zatelli M.C., Tagliati F., Taylor J.E., Rossi R., Culler M.D., degli Uberti E.C. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line TT. J Clin Endocrinol Metab. 86:2001;2161-2169
12. Schulz S., Schmitt J., Wiborny D., Schmidt H., Olbricht S., Weise W., et al. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype- specific antibodies. Clin Cancer Res. 4:1998;2047-2052
13. Schulz S., Pauli S.U., Händel M., Dietzmann K., Firsching R., Hollt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 6:2000;1865-1874
14. Schulz S., Schmitt J., Quednow C., Roessner A., Weise W. Immunohistochemical detection of somatostatin receptors in human ovarian tumors. Gynecol Oncol. 84:2002;235-240
15. Kulaksiz H., Eissele R., Rössler D., Schulz S., Hollt V., Cetin Y., et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 50:2002;52-60
16. Bläker M., de Weerth A., Tometten M., Schulz M., Höppner W., Arlt D., et al. Expression of the cholecystokinin 2-receptor in normal human thyroid gland and medullary thyroid carcinoma. Eur J Endocrinol. 146:2002;89-96
17. Bläker M., Arrenberg P., Stange I., Schulz M., Burghardt S., Michaelis H., et al. The cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT. Regul Pept. 118:2004;111-117
18. Cattaneo M.G., Amoroso D., Gussoni G., Sanguini A.M., Vicentini L.M. A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines. FEBS Lett. 397:1996;164-168
19. Florio T., Yao H., Carey K.D., Dillon T.J., Stork P.J. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol Endocrinol. 13:1999;24-37
20. Sellers L.A., Feniuk W., Humphrey P.P., Lauder H. Activated G protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase. Resultant effects on cell proliferation. J Biol Chem. 274:1999;16423-16430
21. Sharma K., Patel Y.C., Srikant C.B. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol. 13:1999;82-90
22. Sharma K., Patel Y.C., Srikant C.B. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol. 10:1996;1688-1696
23. Teijeiro R., Rios R., Costoya J.A., Castro R., Bello J.L., Devesa J., et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem. 12:2002;31-38
24. Lamberts S.W., de Herder W.W., Hofland L.J. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab. 13:2002;451-457
25. Shojamanesh H., Gibril F., Louie A., Ojeaburu J.V., Bashir S., Abou-Saif A., et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer. 94:2002;331-343
26. Patel Y.C., Srikant C.B. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology. 135:1994;2814-2817
27. Rabinowitz I., Telepak R., Lee F.C. Octreotide scans are positive in a subset of patients with hepatocellular carcinoma. Clin Nucl Med. 27:2002;499-502
28. Lamberts S.W., van der Lely A.J., Hofland L.J. New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol. 146:2002;701-705
29. Bruns C., Lewis I., Briner U., Meno-Tetang G., Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 146:2002;707-716
30. Papotti M., Bongiovanni M., Volante M., Allia E., Landolfi S., Helboe L., et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 440:2002;461-475
31. Reubi J.C., Chayvialle J.A., Franc B., Cohen R., Calmettes C., Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest. 64:1991;567-573
32. Kwekkeboom D.J., Reubi J.C., Lamberts S.W., Bruining H.A., Mulder A.H., Oei H.Y., et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 76:1993;1413-1417
33. Buscail L., Saint-Laurent N., Chastre E., Vaillant J.C., Gespach C., Capella G., et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 56:1996;1823-1827
34. Caplin M., Khan K., Grimes S., Michaeli D., Savage K., Pounder R., et al. Effect of gastrin and anti-gastrin antibodies on proliferation of hepatocyte cell lines. Dig Dis Sci. 46:2001;1356-1366